



Interleukin 22

Guest Editor:

Dr. Derek Pociask

Department of Pulmonary
Critical Care and Environmental
Medicine, Tulane University
School of Medicine, New Orleans,
LA 70112, USA

Deadline for manuscript
submissions:

closed (30 December 2022)

Message from the Guest Editor

Interleukin 22 (IL-22) is a cytokine that has great therapeutic promise. In the 20 years since its discovery, IL-22 has been found to play critical roles in maintenance of mucosal barriers, bacterial clearance, epithelial cell proliferation, and inflammation. The initial implications of IL-22 for psoriasis, atopic dermatitis, and cancer have led to clinical trials investigating the efficacy of inhibiting IL-22 in these disease processes. At the same time, administration of IL-22 is being investigated clinically as a therapeutic approach for COVID-19, alcoholic hepatitis, and graft versus host disease (GVHD). These dichotomous clinical approaches emphasize the great need to better understand the contexts within which IL-22 is pathogenic vs. beneficial. Therefore, this Special Issue welcomes original research and review articles regarding IL-22, the IL-22 receptor, and the IL-22 inhibitor (IL22ra2) in the context of disease and recovery.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of
Odontostomatologic and
Specialized Clinical Sciences,
Sez-Biochimica, Faculty of
Medicine, Università Politecnica
delle Marche, Via Ranieri 65,
60100 Ancona, Italy

Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Biochemistry & Molecular Biology*) / CiteScore - Q1 (*Inorganic Chemistry*)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI